MedPath

Phase II study in combination with Carboplatin and TS-1 for Cancer of unknown primary

Phase 2
Conditions
Cancer of unknown primary
Registration Number
JPRN-UMIN000001236
Lead Sponsor
ational Cancer Center Hospital, Tokyo
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Sex
All
Target Recruitment
35
Inclusion Criteria

Not provided

Exclusion Criteria

a) Specific subgroups of CUP (female(adenocarcinoma, Ax LN metastases), female (adenocarcinoma, peritonitis carcinomatosa), squamous cell carcinoma of cervical LN metastases, etc.) b) history of any malignancies c) massive effusion (thorax or abdominal cavity) d) symptomatic brain metastases e) uncontrolled cormobity (DM, hypertension, infection) f) internal use of phenytoine, flucytosyne, or warfarin

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Response rate (RECIST criteria)
Secondary Outcome Measures
NameTimeMethod
Adverse events (NCI-CTC/AE version 3)
© Copyright 2025. All Rights Reserved by MedPath